Search Result

Results for "

acetyl-CoA inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (46) Acetyl-CoA synthetase (2) ADC Payload (3) AMPK (5) Antibiotic (4) Apoptosis (5) ATP Citrate Lyase (3) Autophagy (3) Bacterial (6) Biochemical Assay Reagents (1) Carnitine Palmitoyltransferase (CPT) (1) Cytochrome P450 (1) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (1) Endogenous Metabolite (3) Environmental Pollutants (1) FABP (1) Fluorescent Dye (3) Free Fatty Acid Receptor (1) Fungal (2) FXR (2) HBV (3) Herbicide (3) Histone Acetyltransferase (3) HIV (3) HMG-CoA Reductase (HMGCR) (1) Insecticide (1) Isotope-Labeled Compounds (1) Lipoxygenase (1) Mitophagy (3) N-myristoyltransferase (1) Oxidative Phosphorylation (1) Parasite (3) PDK-1 (1) PPAR (1) Pyruvate Carboxylase (PC) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (13) RSV (3) STAT (2) Topoisomerase (3)
By Research Areas:	Cancer (16) Cardiovascular Disease (3) Infection (14) Inflammation/Immunology (6) Metabolic Disease (24) Neurological Disease (2)

By Targets:

Acetyl-CoA Carboxylase (46)

Acetyl-CoA synthetase (2)

ADC Payload (3)

AMPK (5)

Antibiotic (4)

Apoptosis (5)

ATP Citrate Lyase (3)

Autophagy (3)

Bacterial (6)

Biochemical Assay Reagents (1)

Carnitine Palmitoyltransferase (CPT) (1)

Cytochrome P450 (1)

Drug Derivative (1)

Drug Intermediate (1)

Drug Metabolite (1)

Endogenous Metabolite (3)

Environmental Pollutants (1)

FABP (1)

Fluorescent Dye (3)

Free Fatty Acid Receptor (1)

Fungal (2)

FXR (2)

HBV (3)

Herbicide (3)

Histone Acetyltransferase (3)

HIV (3)

HMG-CoA Reductase (HMGCR) (1)

Insecticide (1)

Isotope-Labeled Compounds (1)

Lipoxygenase (1)

Mitophagy (3)

N-myristoyltransferase (1)

Oxidative Phosphorylation (1)

Parasite (3)

PDK-1 (1)

PPAR (1)

Pyruvate Carboxylase (PC) (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (13)

RSV (3)

STAT (2)

Topoisomerase (3)

By Research Areas:

Cancer (16)

Cardiovascular Disease (3)

Infection (14)

Inflammation/Immunology (6)

Metabolic Disease (24)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Acetyl-CoA synthetase Acetyl-CoA Carboxylase Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15142

Doxorubicin hydrochloride Maximum Cited Publications 650 Publications Verification Hydroxydaunorubicin hydrochloride; ADR	Topoisomerase ADC Payload AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye	Infection Cancer
Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .

HY-101068

TOFA 10+ Cited Publications RMI14514; MDL14514	Acetyl-CoA Carboxylase	Cancer
TOFA (RMI14514;MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA ).

HY-16901

Firsocostat 20+ Cited Publications ND-630; GS-0976; NDI-010976	Acetyl-CoA Carboxylase	Metabolic Disease
Firsocostat (ND-630; GS-0976; NDI-010976) is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC₅₀ values of 2.1 and 6.1 nM, respectively.

HY-104032

Ac-CoA Synthase-IN-1 5+ Cited Publications	RSV	Infection Metabolic Disease
Ac-CoA Synthase-IN-1 is a potent, reversible *acetate-dependent acetyl-CoA* synthetase 2 (ACSS2)** inhibitor with an IC₅₀ of 0.6 μM . Ac-CoA Synthase-IN-1 inhibits the respiratory syncytial virus (RSV) .

HY-112083

BAY-3827 10+ Cited Publications	AMPK	Cancer
BAY-3827, a chemical probe, is a potent and selective AMPK inhibitor with IC₅₀ values of 1.4 nM at low (10 μM ATP concentration) and 15 nM at high (2 mM ATP concentration). BAY-3827 shows over 500-fold selectivity for most of the 331 kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1 and shows strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines .

HY-134901

WM-3835 5+ Cited Publications	Histone Acetyltransferase Apoptosis	Cancer
WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice .

HY-15142R

Doxorubicin hydrochloride (Standard) 5 Publications Verification Hydroxydaunorubicin hydrochloride (Standard); ADR (Standard)	Reference Standards Topoisomerase ADC Payload AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye	Infection Cancer
Doxorubicin hydrochloride (Standard) is the analytical standard of Doxorubicin hydrochloride. This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .

HY-101842

ND-646 10+ Cited Publications	Acetyl-CoA Carboxylase	Cancer
ND-646 is an orally bioavailable and steric inhibitor of acetyl-CoA carboxylase (ACC) with IC₅₀s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively.

HY-15142A

Doxorubicin Hydroxydaunorubicin	ADC Payload Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV Fluorescent Dye	Infection Cancer
Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy .

HY-15259

CP-640186 5+ Cited Publications	Acetyl-CoA Carboxylase	Metabolic Disease
CP-640186 is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC₅₀s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation .

HY-12942

PF-05175157 3 Publications Verification	Acetyl-CoA Carboxylase	Metabolic Disease
PF-05175157 is broad spectrum acetyl-CoA carboxylase (ACC) inhibitor with IC₅₀s of 27.0, 33.0, 23.5 and 50.4 nM for ACC1 (human), ACC2 (human), ACC1 (rat), ACC2 (rat), respectively.

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-100671

L002	Histone Acetyltransferase STAT	Cardiovascular Disease Inflammation/Immunology Cancer
L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC₅₀ of 1.98 μM . L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation . L002 has the potential for hypertension-induced cardiac hypertrophy and fibrogenesis treatment .

HY-P1123

MEDICA16	ATP Citrate Lyase Free Fatty Acid Receptor Acetyl-CoA Carboxylase	Metabolic Disease
MEDICA16 is an orally active acetyl-CoA carboxylase and ATP-citrate lyase inhibitor. MEDICA16 limits the acetyl-CoA supply for acetyl-CoA carboxylase, inhibits acetyl-CoA carboxylase activity, exerts citrate-competitive inhibitory effects on ATP-citrate lyase, and reduces hepatic AMPK activity. MEDICA16 can be used in research related to insulin resistance, hyperlipidemia, and obesity .

HY-15259A

CP-640186 hydrochloride 5+ Cited Publications	Acetyl-CoA Carboxylase	Metabolic Disease
CP-640186 hydrochloride is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC₅₀s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 hydrochloride can also stimulate muscle fatty acid oxidation .

HY-135981

CMS-121 2 Publications Verification	Acetyl-CoA Carboxylase	Neurological Disease Inflammation/Immunology
CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC₅₀ values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities .

HY-147004

A-908292	Acetyl-CoA Carboxylase	Metabolic Disease
A-908292 is a potent and selective acetyl-CoA carboxylase 2 (ACC2) inhibitor, with an IC₅₀ of 23 nM for human ACC2. A-908292 can be used for the research of fatty acid metabolism . A-908292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152117

Acetyl-CoA Carboxylase-IN-1	Acetyl-CoA Carboxylase Bacterial	Infection
Acetyl-CoA Carboxylase-IN-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor with an IC₅₀ value of ＜5 nM. Acetyl-CoA Carboxylase-IN-1 has antibacterial activity .

HY-N7347

(-)-Hydroxycitric acid lactone Garcinia lactone	ATP Citrate Lyase	Metabolic Disease
(-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis .

HY-107709

MK-4074 4 Publications Verification	Acetyl-CoA Carboxylase	Metabolic Disease
MK-4074 is a liver-specific inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC₅₀ values of approximately 3 nM.

HY-161117

AD-8007	RSV	Cancer
AD-8007 is an acetyl CoA synthase 2 (ACSS2) inhibitor that can cross the blood-brain barrier. AD-8007 can significantly reduce lipid storage and cell colony formation in vitro models, and increase tumor cell death. AD-8007 has anti-cancer activity and can be used in the research of breast cancer .

HY-W012865

Tartronic acid	Carnitine Palmitoyltransferase (CPT) Endogenous Metabolite FABP PPAR	Metabolic Disease
Tartronic acid, a dicarboxylic acid derive, is an inhibitor of the transformation of carbohydrates into fat under fat-deficient diet conditions. Tartronic acid promotes 3T3-L1 adipocyte differentiation by increasing the protein expression of FABP-4, PPARγ and SREBP-1. Tartronic acid promotes de novo lipogenesis and inhibits CPT-1β by upregulating acetyl-CoA and malonyl-CoA. Tartronic acid promotes weight gain and induces adipocyte hypertrophy in epididymal white adipose tissue and lipid accumulation in the livers of high-fat diet induced obese mice. Tartronic acid can be used for lipid metabolic disease research .

HY-W612338

9-Oxononanoic acid 9-ONA	Acetyl-CoA Carboxylase	Inflammation/Immunology
9-Oxononanoic acid (9-ONA) is an orally active acetyl-CoA carboxylase inhibitor. 9-Oxononanoic acid inhibits acetyl-CoA carboxylase via accumulation of long-chain acyl-CoA. 9-Oxononanoic acid increases carnitine palmitoyltransferase, isocitrate dehydrogenase and glucose 6-phosphate dehydrogenase activity to elevate β-oxidation and support NADPH (HY-113324) supplyactivity. 9-Oxononanoic acid stimulates phospholipase A2 activity via post-translational, non-transcriptional mechanisms. 9-Oxononanoic acid can be used for the research of atherothrombosis .

HY-N14257

Andrimid	Bacterial Antibiotic Acetyl-CoA Carboxylase	Infection
Andrimid is a peptide Antibiotic and acetyl-CoA carboxylase inhibitor. Andrimid is produced by symbiotic bacteria of the genus Enterobacter residing in the brown planthopper Nilaparvata lugens. Andrimid exhibits strong specific activity against Xanthomonas campestris pv. oryzae. Andrimid shows no or only weak activity against Gram-positive and Gram-negative bacteria, including most plant pathogenic bacteria. Andrimid can be used in studies related to bacterial infections and rice bacterial blight .

HY-E70394

S-Acetonyl-CoA Acetonyl-coenzyme A	Biochemical Assay Reagents N-myristoyltransferase	Metabolic Disease
S-Acetonyl-CoA (Acetonyl-coenzyme A) is a non-reactive structural analog of acetyl-CoA that acts as a competitive inhibitor against multiple target enzymes. S-Acetonyl-CoA lacks the characteristic thioester group of acetyl-CoA, retaining only a thioether structure. S-Acetonyl-CoA competes with acetyl-CoA for binding to citrate synthase, phosphate transacetylase, carnitine acetyltransferase, and N-myristoyltransferase 1. S-Acetonyl-CoA serves as a reagent for investigating acetyl-CoA-dependent physiological processes .

HY-117262

Propaquizafop	Acetyl-CoA Carboxylase	Others
Propaquizafop is a phenoxyisopropionic acid herbicide and an acetyl-coA carboxylase inhibitor .

HY-147376

hACC2-IN-1	Acetyl-CoA Carboxylase	Metabolic Disease
hACC2-IN-1 is a potent acetyl-CoA carboxylase 2 (ACC2) inhibitor, with an IC₅₀ value of 2.5 μM (hACC2). hACC2-IN-1 could be used for obesity research .

HY-W588256

12-Tridecenoic acid	Endogenous Metabolite Acetyl-CoA Carboxylase	Infection
12-Tridecenoic acid is a metabolite of intestinal flora, which can promote the expression of acetyl-CoA carboxylase α (ACC) and inhibit the expression of carnitine palmitoyltransferase 1A (CPT1A), thereby aggravating hepatic steatosis. 12-Tridecenoic acid aggravates hepatic steatosis by affecting the ACC-CPT1A axis .

HY-179537

CKBA	Acetyl-CoA Carboxylase Drug Derivative	Inflammation/Immunology
CKBA, a derivative of AKBA (HY-N0892) is an inhibitor of acetyl-CoA carboxylase 1 (ACC1), with an IC₅₀ of 5.02 μM. CKBA inhibits the differentiation of Th17 cells and has IC₅₀ values of 3.28 μM for mouse cells and 3.61 μM for human cells. CKBA ointment significantly alleviates psoriasis-like inflammation in mice. CKBA can be used for the study of psoriasis .

HY-147932

ACC1/2-IN-2	Acetyl-CoA Carboxylase	Cancer
ACC1/2-IN-2 (compound PF-3) is a potent ACC1/2 inhibitor with IC₅₀ values of 22 and 48 nM for ACC1 and ACC2, respectively. ACC1/2-IN-2 has antiproliferation activity and can be used for cancer research .

HY-16943

Moiramide B	Bacterial Acetyl-CoA Carboxylase	Infection
Moiramide B is a potent acetyl-CoA carboxylase (ACC) inhibitor with an IC₅₀ value of 6 nM. Moiramide B has antibacterial activity .

HY-123307

Quizalofop Xylafop	Environmental Pollutants Acetyl-CoA Carboxylase	Others
Quizalofop (Xylafop) is a herbicide that inhibits acetyl-CoA carboxylase (ACCase) to reduce the synthesis of fatty acids. Quizalofop can be used to screen EMS (HY-W015854) mutated microalgae for research on improving the performance of microalgae biofuel production .

HY-150191

IMA-1	Lipoxygenase Acetyl-CoA Carboxylase	Metabolic Disease
IMA-1 is an inhibitor that inhibits the interaction between arachidonic acid 12-lipoxygenase (ALOX12) and acetyl-CoA carboxylase 1 (ACC1). IMA-1 significantly blocks the progression of diet-induced non-alcoholic steatohepatitis (NASH) in male mice and crab-eating monkeys, and does not cause hyperlipidemia. IMA-1 can be used for the study of NASH .

HY-127108

ND-654	Acetyl-CoA Carboxylase	Metabolic Disease Cancer
ND-654 is a highly selective acetyl-CoA carboxylase (ACC) inhibitor (IC₅₀: ACC1=3 nM, ACC2=8 nM). ND-654 reduces hepatic lipogenesis, decreases neutrophil recruitment and promotes anti-inflammatory M2 macrophage polarization. ND-654 is promising for research of nonalcoholic steatohepatitis and hepatocellular carcinoma .

HY-178040

Insecticidal agent 26	Acetyl-CoA Carboxylase Pyruvate Carboxylase (PC) Parasite Insecticide	Infection
Insecticidal agent 26 (Compound A11), a spiro insecticidal agent, is a dual-functional inhibitor of pest Acetyl-CoA carboxylase (ACC) and Pyruvate carboxylase (PC). Insecticidal agent 26 has potent insecticidal activity against Sogatella furcifera with a LC₅₀ of 11.0  μg/mL, with significant biosafety to bees. Insecticidal agent 26 can be used for management of white-backed planthoppers (WBPs) .

HY-16901A

Firsocostat (S enantiomer) ND-630 (S enantiomer); GS-0976 (S enantiomer); NDI-010976 (S enantiomer)	Acetyl-CoA Carboxylase	Others
Firsocostat S enantiomer (ND-630 S enantiomer) is the less active S enantiomer of Firsocostat. Firsocostat is an acetyl-CoA carboxylase (ACC) inhibitor.

HY-114575

Cycloxydim BAS 517-02H	Herbicide Acetyl-CoA Carboxylase	Others
Cycloxydim (BAS 517-02H) is a cyclohexanedione oxime herbicide. Cycloxydim can inhibits the acetyl-CoA carboxylase .

HY-121273

Diclofop Dichlorfop acid; (±)-Diclofop	Acetyl-CoA Carboxylase Parasite Drug Metabolite	Infection
Diclofop (Dichlorfop acid) is an acetyl-CoA carboxylase (ACC) inhibitor. Diclofop is also the major metabolite of the herbicide Diclofop-methyl (HY-136367). Diclofop exhibits antimalarial activity with an IC₅₀ of 210 μM against P. falciparum .

HY-16946

CP-610431	Acetyl-CoA Carboxylase	Metabolic Disease
CP-610431 is a reversible, ATP-uncompetitive, isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor. CP-610431 inhibits ACC1 and ACC2 with IC₅₀s of ~50 nM. CP-610431 can be used for the research of metabolic syndrome .

HY-173565

ACC-IN-1	Acetyl-CoA Carboxylase	Inflammation/Immunology
ACC-IN-1 (Compound B1) is an allosteric inhibitor of acetyl-CoA carboxylase (ACC). ACC-IN-1 targets ACC to regulate lipid metabolism, which can improve liver steatosis, inflammation related to non-alcoholic steatohepatitis (NASH) .

HY-16901R

Firsocostat (Standard) ND-630 (Standard); GS-0976 (Standard); NDI-010976 (Standard)	Acetyl-CoA Carboxylase Reference Standards	Metabolic Disease
Firsocostat (Standard) is the analytical standard of Firsocostat. This product is intended for research and analytical applications. Firsocostat (ND-630; GS-0976; NDI-010976) is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively.

HY-139134

S-2E	HMG-CoA Reductase (HMGCR) Acetyl-CoA Carboxylase	Cardiovascular Disease
S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research .

HY-147930

ACC1/2-IN-1	Acetyl-CoA Carboxylase	Cancer
ACC1/2-IN-1 (compound 4s) is a potent ACC1/2 inhibitor with IC₅₀ values of 98.06 and 29.43 nM for ACC1 and ACC2, respectively. ACC1/2-IN-1 can be used for cancer research .

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-111223

Tralkoxydim PP604; ICIA 0604; FD-4026	Acetyl-CoA Carboxylase	Others
Tralkoxydim is a cyclohexanedione herbicide that inhibits Acetyl-CoA Carboxylase in corn .

HY-W747605

Tepraloxydim	Acetyl-CoA Carboxylase Herbicide	Others
Tepraloxydim is an acetyl-CoA carboxylase inhibitor with weed control activity .

HY-121427

Fluazifop	Acetyl-CoA Carboxylase	Others
Fluazifop is a grass-selective herbicide via inhibiting acetyl-CoA carboxylase .

HY-111223R

Tralkoxydim (Standard) PP604 (Standard); ICIA 0604 (Standard); FD-4026 (Standard)	Acetyl-CoA Carboxylase Reference Standards	Others
Tralkoxydim (Standard) is the analytical standard of Tralkoxydim. This product is intended for research and analytical applications. Tralkoxydim is a cyclohexanedione herbicide that inhibits Acetyl-CoA Carboxylase in corn .

HY-117262R

Propaquizafop (Standard)	Reference Standards Acetyl-CoA Carboxylase	Others
Propaquizafop (Standard) is the analytical standard of Propaquizafop. This product is intended for research and analytical applications. Propaquizafop is a phenoxyisopropionic acid herbicide and an acetyl-coA carboxylase inhibitor .

HY-N7347R

(-)-Hydroxycitric acid lactone (Standard) Garcinia lactone (Standard)	Reference Standards ATP Citrate Lyase	Metabolic Disease
(-)-Hydroxycitric acid lactone (Standard) is the analytical standard of (-)-Hydroxycitric acid lactone. This product is intended for research and analytical applications. (-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis .

Cat. No.	Product Name

HY-L231

TCA Cycle Metabolite Compound Library

26 compounds

The TCA cycle (tricarboxylic acid cycle)—is also known as the Krebs cycle or the citric acid cycle (CAC). The TCA cycle is a series of chemical reactions that release stored energy through the oxidation of acetyl-CoA in carbohydrates, fats, and proteins.

For decades, the TCA cycle has been considered as the central pathway for cell oxidative phosphorylation to produce energy and biosynthesis. Research shows that TCA cycle is associated with many diseases, especially cancer. In colon carcinoma, liver cancer and other cancers, there are mutations that lead to the imbalance of TCA cycle metabolites, indicating that TCA cycle may be related to the occurrence of cancer. Understanding the role and molecular mechanism of TCA cycle in inhibiting or promoting cancer progression will promote the development of new metabolite-based cancer treatment methods in the future.

MCE supplies a unique collection of 26 key intermediates of the TCA cycle, which can be utilized for TCA-related research and metabolomics identification studies.

HY-L148

TCA Cycle Compound Library

72 compounds

MCE supplies a unique collection of 72 compounds related to the TCA cycle. MCE TCA Cycle Compound Library is a useful tool for the TCA cycle related research and anti-cancer drug development.

Cat. No.	Product Name	Category	Target	Chemical Structure